SCHEMBL4020114

SCHEMBL4020114

O=C(O)c1cc(Cl)cnc1OCCc1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 5/20 0.53
PTGER2 P43116 2/20 0.53
BRS3 P32247 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
FFAR4 Q5NUL3 1/20 0.41
CYP2C9 P11712 1/20 0.40
PTGER1 P34995 1/20 0.40
KDM4E B2RXH2 1/20 0.40
DHODH Q02127 1/20 0.39
HTR2C P28335 1/20 0.39
SLC6A4 P31645 1/20 0.39
HTR2B P41595 1/20 0.39
SLC2A1 P11166 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
ELOVL1 Q9BW60 1/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
PTPN1 P18031 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014183 0.92 PTGER4 (0.44) PTGER4PTGER2BRS3FFAR4PTGER1
SCHEMBL4443148 0.80 PTGER4 (0.65) PTGER4PTGER2CYP2C9
SCHEMBL4014226 0.80 PTGER4 (0.75) PTGER4PTGER2
SCHEMBL4012174 0.78 NR4A2 (0.50) PTGER4PTGER2PTGER1SLC6A4MRGPRX4
SCHEMBL11452714 0.77 CYP1A2 (0.45) PTGER4PTGER2CYP2C9KDM4EDHODH
SCHEMBL4446740 0.77 PTGER4 (0.47) PTGER4PTGER2BRS3CYP2C9PTGER1
SCHEMBL11453574 0.76 MEN1 (0.47) PTGER4CYP2C9KDM4EDHODH
SCHEMBL1505330 0.76 PLAU (0.45) PTGER4PTGER2FFAR4CYP2C9KDM4E
SCHEMBL4014085 0.76 SIRT2 (0.43) PTGER4BRS3CYP2C9DHODHSIRT2
Hydrochloric Acid SCHEMBL11551619 0.75 MEN1 (0.46) PTGER4CYP2C9KDM4EDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756043-B1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS RAQUALIA PHARMA INC (JP) 2009-07-01 EP disclosed
WO-2005102389-A9 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2009-04-30 WO disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
EP-1756043-A1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS Pfizer, Inc. (US) 2007-02-28 EP disclosed
EP-1740211-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-01-10 EP disclosed
US-20050250818-A1 Ortho substituted aryl or heteroaryl amide compounds PFIZER INC 2005-11-10 US disclosed
WO-2005105733-A1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2005-11-10 WO disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250818-A1 Ortho substituted aryl or heteroaryl amide compounds OPRL1, PTGER1, OPRM1 PTGER4 19/4885PTGER2 6/4885BRS3 123/4885
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PTGER4, PTGER2, OPRL1 PTGER4 1/4885PTGER2 2/4885BRS3 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.